Novartis joins longitudinal study for RWD

By Maggie Lynch

- Last updated on GMT

(Image: Getty/solarseven)
(Image: Getty/solarseven)

Related tags RWD RWE Novartis Clinical data Clinical trial Clinical research Dermatology

Novartis Pharma AG partners with Target PharmaSolutions to support its global longitudinal observational study designed to generate real-world clinical data.

The Target-Derm registry evaluates adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs).

It will begin by focusing on patients with atopic dermatitis and then expand to include other skin conditions, such as hidradenitis suppurativa, alopecia areata, and vitiligo.

Matt Casbon, chief business officer, of Target PharmaSolutions, told us that using the longitudinal cohort design will “enable characterization of IMISC disease activity and comorbid medical conditions over time, and will cultivate a foundation for more targeted investigations.”

Novartis will join the Target-Derm community as a member of the advisory committee, part of Target PharmaSolution’s model. Novartis will weigh in on the data analysis and research insight, as well as providing financial support. 

Longitudinal RWD

Target-Derm is the sixth disease category real-world study Target PharmaSolutions has taken on since 2015. It has ongoing studies in nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV).

A spokesperson for Novartis told us that the company is already a partner on the Target-NASH study and has seen the possibilities of what this type of study can provide at multiple stages of drug development.

“This information [collected from the registry] will inform our drug development and in the end help our ambitions to reimagine the lives of patients who are waiting for innovation in immune-dermatology,”​ the Novartis spokesperson continued.

Target-Derm will be conducted Using Target PharmaSolution’s standardized model. Using this model, “[Target PharmaSolutions]organizes stakeholders through a turn-key, multidisciplinary approach that includes pharmaceutical partners, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate regulatory grade, longitudinal, real-world clinical data,”​ said Casbon.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more